How far is it from the market value of 100 billion yuan after "one dismantling and three dismantling"?

On June 13, Yaoming biotechnology was successfully listed on the stock exchange of Hong Kong with an opening price of HK $25.00 and a closing price of HK $27.950 as of the morning According to Yao's announcement, the offering price is set at HK $20.6 per share, with 192982500 shares to be issued and a total of HK $3.975 billion raised As the second part of "one dismantling and three dismantling" after the privatization of Wuxi apptec, Wuxi apptec is another important play in the pharmaceutical sector of Hong Kong stock after the listing of China Resources pharmaceutical   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); Box sizing: border box! Im portant; word wrap: break word! Im portant; "> as the largest R & D service provider of biological agents in China, Yaoming bio mainly provides a series of comprehensive services related to the discovery, development and production of biological agents At present, the business scope covers five stages: drug discovery, preclinical development, early (phase I and II) clinical development, late (phase III) clinical development and commercial production According to the public data, from 2014 to 2016, Yaoming biology achieved operating revenues of RMB 332 million, RMB 557 million and RMB 989 million respectively, with net profits of RMB 41.98 million, RMB 44.51 million and RMB 141 million respectively It can be seen from the above data that in recent two years, both the revenue and net profit of YaoMing bio have achieved a substantial growth, with the revenue growth maintained at 65%, while the growth rate of net profit last year was more than 200% Yaomingbio said that the profit growth was mainly due to the additional projects obtained and the increasing demand of customers for services as the ongoing projects were promoted   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> strong R & D strength: Yaoming biology, born in Yaoming Kant, was registered as an independent company at the beginning of 2014 With more than three years of growth, it has a strong technical strength and an open technology platform, supported by a team of 732 scientists, including 475 with master's degree and 114 with doctor's degree At present, Yaoming biology has three operating bases in Wuxi, Shanghai and Suzhou respectively, and operates the world's top two cell culture and development laboratories, equipped with more than 260 sets of bioreactors with independent capacity ranging from 1 to 200 liters At the same time, in 2015, the company began to build new commercial API cGMP manufacturing facilities in Wuxi base to expand its commercial capacity and meet the expanding market demand In addition, in June 2017, Yaoming bio will start to build a new facility with a planned capacity of 7000 liters in the Shanghai base, with a view to increasing customers' demand for commercial production of biological agents and clinical development of later biological agents At present, Yaoming biology has successfully promoted 15 biological preparations to the stage of application of experimental new drugs for launching global clinical trials, and 32 molecules to the stage of clinical trials in China In addition, the company has developed 191 cell lines for therapeutic protein use and 72 cell-based bioassay methods, and has produced more than 330 batches of biological agents, with a success rate of 97.6%   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> the layout of" one break three "listing One of the reasons why the listing of YaoMing bio has attracted the attention of the capital market is that it relies on the capital operation background of the parent company" Yaoming Kant "privatization to return to the" one break three "listing For the insiders, another important reason is the rapid outbreak of bio medicine in recent years Founded in 2000, Wuxi apptec started with pharmaceutical R & D outsourcing service (CRO), providing a series of laboratory R & D, research and production services to global pharmaceutical companies, biotechnology companies and medical device companies After gaining a large market share, Wuxi apptec was listed on the New York Stock Exchange on August 9, 2007 At the end of 2015, Wuxi apptec completed privatization and delisting, with a market value of about 3.3 billion US dollars at that time In March this year, Wuxi apptec released a listing guidance announcement on its official website, which means that the third step of its capitalization, the listing of a shares of Wuxi apptec, is officially on the agenda Since then, it has been reported that Wuxi apptec plans to raise 20 billion yuan through the Shanghai IPO In addition to the return of the company's main body to a shares, Hequan pharmaceutical, a subsidiary of Wuxi apptec that undertakes cro business, has also landed on the new third board The landing of Wuxi apptec on the Hong Kong Stock Exchange also marks the completion of the second step of "one to three" Hequan pharmaceutical was founded in 2003 and listed on the new third board in April 2015 As a research-oriented and customer-centered enterprise, it has rapidly grown into one of the leaders in the field of pharmaceutical process research and development The company is committed to technological innovation and commercial application of global pharmaceutical technology, and provides innovative pharmaceutical R & D and production outsourcing services for international mainstream pharmaceutical enterprises According to the annual report of Hequan pharmaceutical, the company continued to develop rapidly in 2016 and showed a good growth momentum In 2016, the operating revenue was 1.638 billion yuan, an increase of 29.07% over the previous year; the net profit attributable to the shareholders of the listed company was 436 million yuan, an increase of 32.01% over 2015 As of the closing on the morning of June 13, the total market value of Hequan Pharmaceutical Co., Ltd was 18.518 billion yuan, and the total market value of YaoMing biological Co., Ltd was 31.699 billion Hong Kong dollars Yaoming Kant has also queued up in A-share market It is said that the total value of the three companies will exceed 100 billion yuan after the "one to three" fund-raising   none="shifuMouseDown('shifu_t_002')" style="margin: 1em auto; padding: 0.5em 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: 'Hiragino Sans GB', 'Microsoft YaHei', Arial, sans-serif; font-size: 16px; line-height: 25.6px; border: none; text-align: center; width: 670px; box-sizing: border-box !im portant; Word-wrap: break-word! Im portant; "> In May this year, yaomingkant, who has entered the guidance period of listing, announced the completion of the acquisition of Huiyuan biology, making it return to A-share for further After the successful landing of yaomingbio on the Hong Kong stock exchange, the second step of the listing layout of "one break three" has been completed It is believed that the return of the main body of yaomingkant, which is the most concerned in the industry, to the A-share market will not make you wait too long Now, is it far away from the market value of 100 billion yuan for Wuxi apptec to develop in three ways? Source: annual report of listed companies, Dongfang fortune.com